Nonetheless, in view of established CSC signatures for other heterogeneous tumor entities (e.g., breast cancer) and the conservation of certain CSC markers throughout different tumor entities (e.g., CD133), we are confident that using a particular marker profile for definition of CSC from various ovarian tumor models is a reasonable approach. The gene discussed is PROM1; the disease is neoplasm.